DOCSLIB.ORG

ORIGINAL ARTICLE Recurrent Translocations Involving the IRF4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ORIGINAL ARTICLE Recurrent Translocations Involving the IRF4 Leukemia (2009) 23, 574–580 & 2009 Macmillan Publishers Limited All rights reserved 0887-6924/09 $32.00 www.nature.com/leu ORIGINAL ARTICLE Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas AL Feldman, M Law, ED Remstein, WR Macon, LA Erickson, KL Grogg, PJ Kurtin and A Dogan Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA Oncogenes involved in recurrent chromosomal translocations In this paper, we show for the first time the presence of serve as diagnostic markers and therapeutic targets in translocations involving the multiple myeloma oncogene-1/ hematopoietic tumors. In contrast to myeloid and B-cell neoplasms, translocations in peripheral T-cell lymphomas interferon regulatory factor-4 (IRF4) locus on 6p25 in PTCLs. On (PTCLs) are poorly understood. Here, we identified recurrent the basis of the observation of a PTCL, unspecified (PTCL-U), translocations involving the multiple myeloma oncogene-1/ with a karyotype including t(6;14)(p25;q11.2), we studied 169 interferon regulatory factor-4 (IRF4) locus in PTCLs. IRF4 PTCLs and found 12 with IRF4 translocations (including the translocations exist in myeloma and some B-cell lymphomas, index case). Two had t(6;14)(p25;q11.2) translocations that but have not been reported earlier in PTCLs. We studied 169 fused the IRF4 and T-cell receptor-alpha (TCRA) gene loci. Both PTCLs using fluorescence in situ hybridization and identified 12 cases with IRF4 translocations. Two cases with t(6;14) were cytotoxic PTCL-Us that presented in the bone marrow and (p25;q11.2) had translocations between IRF4 and the T-cell rapidly developed skin lesions. Such tumors might represent a receptor-alpha (TCRA) locus. Both were cytotoxic PTCLs, distinct clinicopathologic entity. unspecified (PTCL-Us) involving bone marrow and skin. In Eight cutaneous ALCLs (C-ALCLs) had translocations invol- total, 8 of the remaining 10 cases were cutaneous anaplastic ving IRF4 but not TCRA (57% of C-ALCLs tested). One systemic large-cell lymphomas (ALCLs) without TCRA rearrangements ALK-negative ALCL and an additional PTCL-U showed translo- (57% of cutaneous ALCLs tested). These findings identified IRF4 translocations as a novel recurrent genetic abnormality in cations involving IRF4 but not TCRA. IRF4 translocations were PTCLs. Cytotoxic PTCL-Us involving bone marrow and skin and not detected in ALK-positive ALCLs. C-ALCL is an indolent containing IRF4/TCRA translocations might represent a distinct disease that currently lacks specific pathologic features to clinicopathologic entity. Translocations involving IRF4 but not distinguish it from skin involvement by systemic ALK-negative TCRA appear to occur predominantly in cutaneous ALCLs. ALCL,7,8 which is aggressive and often fatal.1,2 Testing for IRF4 Detecting these translocations may be useful in lymphoma translocations may have clinical diagnostic utility in C-ALCL. diagnosis. Further, due to its involvement in translocations, Although molecular pathways associated with ALK transloca- MUM1/IRF4 protein may play an important biologic role in some 9 PTCLs, and might represent a possible therapeutic target. tions in ALK-positive ALCLs have been studied extensively, Leukemia (2009) 23, 574–580; doi:10.1038/leu.2008.320; corresponding pathways in ALCLs lacking ALK translocations published online 6 November 2008 are poorly understood. MUM1/IRF4 protein could play a Keywords: MUM1; IRF4; PTCL; ALCL; translocation; cutaneous biologic role in PTCLs with IRF4 translocations, as IRF4 is lymphoma oncogenic in vitro.10 Utilization of MUM1/IRF4 as a therapeutic target in patients with PTCL merits exploration. Materials and methods Introduction Cases Peripheral T-cell lymphomas (PTCLs) are malignant neoplasms We studied specimens from 169 patients with PTCL diagnosed of mature (peripheral) T lymphocytes, and represent approxi- by WHO (World Health Organization) criteria.1 There were 104 mately 10% of non-Hodgkin lymphomas.1 Despite treatment men and 65 women (M:F ratio, 1.6:1), with a mean age of 58 with conventional chemotherapy, the majority of patients with years (range, 5–92 years). Cases included 23 angioimmuno- PTCLs die of their disease.2 New, targeted therapies might be blastic T-cell lymphomas (13%), 72 PTCL-Us (43%), 18 ALK- aimed at genes involved in recurrent chromosomal transloca- positive ALCLs (11%), 24 ALK-negative ALCLs (14%), 14 tions,3–5 but, in contrast to myeloid neoplasms and B-cell C-ALCLs (8%) and 18 other PTCLs (Table 1). The study was lymphomas,1 translocations in most PTCLs remain poorly approved by the Institutional Review Board and the Biospeci- understood. Identifying novel recurrent translocations in PTCLs mens Committee of Mayo Clinic. may also help define specific disease entities and serve as the basis for clinical diagnostic testing, as they have in the case of Fluorescence in situ hybridization chromosomal translocations involving ALK in ALK-positive 6 IRF4 and TCRA fluorescence in situ hybridization (FISH) probes anaplastic large-cell lymphomas (ALCLs). However, ALK- 11–13 were developed as described earlier. BAC clones (Supple- positive ALCLs represent only about 6% of PTCLs.2 mentary Table S1) were identified using the University of California Santa Cruz Genome Browser (http://www.genome. Correspondence: Dr AL Feldman, Department of Laboratory Medicine UCSC.edu) and ordered from ResGen Invitrogen (Carlsbad, CA, and Pathology, Mayo Clinic, 200 1st St SW, Hilton 1152D, Rochester, USA). As telomeric IRF4 clones showed minimal cross- MN 55905, USA. E-mail: [email protected] hybridization to 16p11, positive cases were confirmed using a Received 7 May 2008; revised 28 August 2008; accepted 18 second breakapart IRF4 probe (probe no. 2; Supplementary September 2008; published online 6 November 2008 Table S1). BAC DNA was isolated using the Qiagen (Valencia, IRF4 translocations in PTCLs AL Feldman et al 575 Table 1 IRF4 translocations and MUM1/IRF4 protein expression in peripheral T-cell lymphomas Diagnosis FISH Immunohistochemistry No. of positivesa (%) No. of positivesa (%) Angioimmunoblastic T-cell lymphoma 0/19 (0) 0/23 (0) PTCL, unspecified 3/64 (5) 20/72 (28) CD30 positive 1/17 (6) 13/18 (72) CD30 negative 2/47 (4) 7/54 (13) Anaplastic large cell lymphoma, ALK positive 0/18 (0) 16/17 (94) Anaplastic large cell lymphoma, ALK negative 1/23 (4) 20/22 (91) Cutaneous anaplastic large cell lymphoma 8/14 (57) 13/14 (93) T-cell large granular lymphocyte leukemia 0/4 (0) 0/4 (0) Hepatosplenic T-cell lymphoma 0/3 (0) 0/3 (0) Subcutaneous panniculitis-like T-cell lymphoma F 0/1 (0) Enteropathy-associated T-cell lymphoma 0/2 (0) 0/2 (0) Extranodal NK/T-cell lymphoma, nasal type 0/8 (0) 0/8 (0) Total 12/155 (8) 69/166 (42) Abbreviations: FISH, fluorescence in situ hybridization; PTCL, peripheral T-cell lymphoma. aIncludes informative cases only, of 169 total cases tested. CA, USA) Plasmid Maxi Kit and fluorescently labeled using tissue or tissue microarray sections were pretreated in 1 mM SpectrumOrange-dUTP or SpectrumGreen-dUTP and the Abbott EDTA buffer at pH 8.0 for 30 min at 98 1C (PT Module; Lab Molecular (Des Plaines, IL, USA) Nick Translation Kit. Cen- Vision, Fremont, CA, USA), then stained for MUM1/IRF4 using a tromeric and telomeric BAC DNA were labeled with different monoclonal mouse anti-human antibody (MUM1p, 1:50; Dako). fluorophores for breakapart probes, and with the same Detection was with Dual Link Envision þ /DAB þ (Dako). fluorophore for dual-fusion (D-FISH) probes. Probe validation Scoring was performed in correlation with hemotoxylin and was conducted based on earlier described ‘familiarization’ eosin and appropriate immunostains (for example, CD20 and procedures.14 Specificity of hybridization was confirmed on CD3). MUM1/IRF4 was considered positive when 430% of metaphases from a splenic marginal zone lymphoma with IRF4/ tumor cells demonstrated nuclear staining. Technical factors IGH fusion,13 a PTCL with a TCRA translocation,11 and normal precluded scoring in rare cases. Diagnosis of C-ALCL required samples. TCRB and TCRG probes were purchased from Dako CD30 positivity in 475% of tumor cells, as per WHO criteria.1 (Carpinteria, CA, USA). The upper limit of the normal range for This cutoff was also used to define CD30 positivity in cases of each probe was determined using a 95% confidence interval as PTCL-U. described earlier.11,14 Upper limits of normal for IRF4, TCRA, TCRB and TCRG were 6, 9, 5 and 6%, respectively. Paraffin tissue microarrays were constructed as described.3,11,12 Conventional cytogenetics In cases with insufficient tissue, whole-tissue sections were Results of karyotype analysis prepared at the time of biopsy analyzed. B5- and formalin-fixed cases were included, as we using earlier described methods19 were reviewed retrospectively have shown similar FISH results with both fixatives.15,16 FISH was when available. performed as described earlier.11 Sections were sequentially immersed in Citrisolve, Lugol solution and sodium thiocyanate. Slides were microwaved for 5 min in citrate buffer, then digested Results and discussion in 0.4% pepsin solution at 37 1C. FISH reagent (10 ml; 7 mlLSI buffer and 3 ml probe) was placed on each slide and slides were We identified 12 PTCLs with IRF4 translocations among 155 cover-slipped, denatured and incubated in a humidified chamber PTCLs with informative FISH results (8%; Tables 1 and 2). These at 37 1C for 12 h. Slides were washed, counterstained with 40, included 3/64 PTCL-Us (5%), 1/23 ALK-negative ALCLs (4%) 6-diamidino-2-phenylindole dihydrochloride, and analyzed by and 8/14 C-ALCLs (57%). IRF4 translocations were not seen in a microscopist (ML) using a fluorescent microscope with ALK-positive ALCLs, angioimmunoblastic T-cell lymphomas or appropriate filter sets. A minimum of 50 cells and a maximum other PTCL subtypes. MUM1/IRF4 protein was detected in the of 200 cells were scored per case.
Load more

Recommended publications
  • The Lymphoma and Multiple Myeloma Center
    The Lymphoma and Multiple Myeloma Center What Sets Us Apart We provide multidisciplinary • Experienced, nationally and internationally recognized physicians dedicated exclusively to treating patients with lymphoid treatment for optimal survival or plasma cell malignancies and quality of life for patients • Cellular therapies such as Chimeric Antigen T-Cell (CAR T) therapy for relapsed/refractory disease with all types and stages of • Specialized diagnostic laboratories—flow cytometry, cytogenetics, and molecular diagnostic facilities—focusing on the latest testing lymphoma, chronic lymphocytic that identifies patients with high-risk lymphoid malignancies or plasma cell dyscrasias, which require more aggresive treatment leukemia, multiple myeloma and • Novel targeted therapies or intensified regimens based on the other plasma cell disorders. cancer’s genetic and molecular profile • Transplant & Cellular Therapy program ranked among the top 10% nationally in patient outcomes for allogeneic transplant • Clinical trials that offer tomorrow’s treatments today www.roswellpark.org/partners-in-practice Partners In Practice medical information for physicians by physicians We want to give every patient their very best chance for cure, and that means choosing Roswell Park Pathology—Taking the best and Diagnosis to a New Level “ optimal front-line Lymphoma and myeloma are a diverse and heterogeneous group of treatment.” malignancies. Lymphoid malignancy classification currently includes nearly 60 different variants, each with distinct pathophysiology, clinical behavior, response to treatment and prognosis. Our diagnostic approach in hematopathology includes the comprehensive examination of lymph node, bone marrow, blood and other extranodal and extramedullary tissue samples, and integrates clinical and diagnostic information, using a complex array of diagnostics from the following support laboratories: • Bone marrow laboratory — Francisco J.
    [Show full text]
  • Therapeutic Effect and Mechanism of Ibrutinib Combined with Dexametha- Sone on Multiple Myeloma
    ORIGINAL ARTICLES Hematology Department of The Second Hospital1, Cheeloo College of Medicine, Shandong University; Department of Hematology of Jining No. 1 People’s Hospital2; Institute of Biotherapy for Hematological Malignancies of Shandong University3; Shandong University-Karolinska Institute Collaborative Laboratory for Stem Cell Research4; Hematology Department of Linyi Central Hospital5; Hematology Department of Binzhou Medical University Hospital6; Institute of Medical Sciences, The Second Hospital, Cheeloo College of Medicine, Shandong University7, Jinan, Shandong, China Therapeutic effect and mechanism of ibrutinib combined with dexametha- sone on multiple myeloma SHENGLI LI1,2, LIKUN SUN1,3,4, QIAN ZHOU1,5, SHUO LI1,6, XIAOLI LIU1,3,4, JUAN XIAO1,3,4, YAQI XU1,3,4, FANG WANG7, YANG JIANG1,3,4,*, CHENGYUN ZHENG1,3,4 Received November 14, 2020, accepted December 2020 *Correspondence author: Yang Jiang, Hematology Department, the Second Hospital of Shandong University, 247th of Beiyuan Rd., Jinan, Shandong, China [email protected] Pharmazie 76: 92-96 (2021) doi: 10.1691/ph.2021.0917 Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase and has proven to be an effective agent for B-cell-mediated hematological malignancies, including multiple myeloma (MM). Several clinical trials of ibrutinib treatment combined with dexamethasone (DXMS) for relapsed MM have demonstrated high response rates, however, the mechanism still remains unclear. In this study, we explored the therapeutic effect and mechanism of ibrutinib combined with DXMS on MM in vitro and vivo. The apoptosis of MM cell lines and mononuclear cells from MM patients’ bone marrow induced by ibrutinib combined with DXMS was detected by flow cytometry and the expression of apoptosis-related proteins were detected by Western blot.
    [Show full text]
  • What Is Multiple Myeloma?
    cancer.org | 1.800.227.2345 About Multiple Myeloma Overview If you have been diagnosed with multiple myeloma or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Multiple Myeloma? Research and Statistics See the latest estimates for new cases of multiple myeloma and deaths in the US and what research is currently being done. ● Key Statistics About Multiple Myeloma ● What’s New in Multiple Myeloma Research? What Is Multiple Myeloma? Cancer starts when cells begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas. To learn more about how cancers start and spread, see What Is Cancer?1 Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is made up of several types of cells that work together to fight infections and other 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 diseases. Lymphocytes (lymph cells) are one of the main types of white blood cells in the immune system and include T cells and B cells. Lymphocytes are in many areas of the body, such as lymph nodes, the bone marrow, the intestines, and the bloodstream. When B cells respond to an infection, they mature and change into plasma cells. Plasma cells make the antibodies (also called immunoglobulins) that help the body attack and kill germs. Plasma cells, are found mainly in the bone marrow.
    [Show full text]
  • Lymphoproliferative Disorders
    Lymphoproliferative disorders Objectives: • To understand the general features of lymphoproliferative disorders (LPD) • To understand some benign causes of LPD such as infectious mononucleosis • To understand the general classification of malignant LPD Important. • To understand the clinicopathological features of chronic lymphoid leukemia Extra. • To understand the general features of the most common Notes (LPD) (Burkitt lymphoma, Follicular • lymphoma, multiple myeloma and Hodgkin lymphoma). Success is the result of perfection, hard work, learning Powellfrom failure, loyalty, and persistence. Colin References: Editing file 435 teamwork slides 6 girls & boys slides Do you have any suggestions? Please contact us! @haematology436 E-mail: [email protected] or simply use this form Definitions Lymphoma (20min) Lymphoproliferative disorders: Several clinical conditions in which lymphocytes are produced in excessive quantities (Lymphocytosis) increase in lymphocytes that are not normal Lymphoma: Malignant lymphoid mass involving the lymphoid tissues. (± other tissues e.g: skin, GIT, CNS ..) The main deference between Lymphoma & Leukemia is that the Lymphoma proliferate primarily in Lymphoid Tissue and cause Mass , While Leukemia proliferate mainly in BM& Peripheral blood Lymphoid leukemia: Malignant proliferation of lymphoid cells in Bone marrow and peripheral blood. (± other tissues e.g: lymph nodes, spleen, skin, GIT, CNS ..) BCL is an anti-apoptotic (prevent apoptosis) Lymphocytosis (causes) 1- Viral infection: 2- Some* bacterial
    [Show full text]
  • Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Version Date: 29JAN2019 Principal Investigator: Catherine J
    Protocol name: Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Version Date: 29JAN2019 Principal Investigator: Catherine J. Lee, MD Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Lead Org. ID: HCI98381/IRB# 98381 CTO#HCI-17-HEME-07 ClinicalTrials.gov ID – NCT03303950 Principal Investigator Catherine J. Lee, MD Blood & Marrow Transplant Program University of Utah 2000 Circle of Hope, Rm 2152 Salt Lake City, UT 84132 Phone: (801) 587-0231 Email: [email protected] Sub-investigator(s) Douglas Sborov, MD Clinical Instructor, Department of Medicine Phone: (801) 581-8394 Email: [email protected] Vedran Radojcic, MD Assistant Professor, Department of Medicine Phone: (801) 213-6109 Email: [email protected] Daniel R. Couriel, MD, MS Director, Blood & Marrow Transplant Program Professor, Department of Medicine Phone: (801) 587-4056 Email: [email protected] Jo-Anna Reems, PhD (Laboratory) Scientific Director, Cell Therapy & Regenerative Medicine Research Professor, Department of Medicine Phone: (801) 585-6262 Email: [email protected] Protocol name: Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Version Date: 29JAN2019 Principal Investigator: Catherine J. Lee, MD Michael Boyer, MD Associate Professor, Department of Medicine Phone: (801) 585-3229 Email: [email protected] Josef Prchal, MD Professor, Department of Medicine Phone: (801) 585-3229 Email: [email protected] Tibor Kovacsovics, MD Associate Professor,
    [Show full text]
  • Xgeva (Denosumab) Injection, for Subcutaneous Use Calcium and Vitamin D
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypocalcemia: Xgeva can cause severe symptomatic hypocalcemia, and These highlights do not include all the information needed to use fatal cases have been reported. Correct hypocalcemia prior to initiating XGEVA® safely and effectively. See full prescribing information for Xgeva. Monitor calcium levels during therapy, especially in the first XGEVA. weeks of initiating therapy, and adequately supplement all patients with Xgeva (denosumab) injection, for subcutaneous use calcium and vitamin D. (5.3) Initial U.S. Approval: 2010 • Osteonecrosis of the jaw (ONJ) has been reported in patients receiving Xgeva. Perform an oral examination prior to starting Xgeva. Monitor for symptoms. Avoid invasive dental procedures during treatment with ------------------------------RECENT MAJOR CHANGES-----------------------­ Xgeva. (5.4) Indications and Usage, Multiple Myeloma and Bone Metastasis from Solid • Atypical femoral fracture: Evaluate patients with thigh or groin pain to Tumors (1.1) 01/2018 rule out a femoral fracture. (5.5) Warnings and Precautions, Multiple Vertebral Fractures (MVF) Following • Hypercalcemia Following Treatment Discontinuation in Patients with Treatment Discontinuation (5.7) 01/2018 Growing Skeletons: Monitor patients for signs and symptoms of Warnings and Precautions, Embryo-Fetal Toxicity (5.8) 01/2018 hypercalcemia and treat appropriately. (5.6) • Multiple Vertebral Fractures (MVF) Following Treatment ---------------------------INDICATIONS AND USAGE---------------------------- Discontinuation: When Xgeva treatment is discontinued, evaluate the Xgeva is a RANK ligand (RANKL) inhibitor indicated for: individual patient’s risk for vertebral fractures. (5.7) • Prevention of skeletal-related events in patients with multiple myeloma • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of and in patients with bone metastases from solid tumors. (1.1) reproductive potential of potential risk to the fetus and to use effective • Treatment of adults and skeletally mature adolescents with giant cell contraception.
    [Show full text]
  • Burkitt Lymphoma
    Board Review- Part 2B: Malignant HemePath 4/25/2018 Small Lymphocytic Lymphoma SLL: epidemiology SLL: 6.7% of non-Hodgkin lymphoma. Majority of patients >50 y/o (median 65). M:F ratio 2:1. Morphology • Lymph nodes – Effacement of architecture, pseudofollicular pattern of pale areas of large cells in a dark background of small cells. Occasionally is interfollicular. – The predominant cell is a small lymphocyte with clumped chromatin, round nucleus, ocassionally a nucleolus. – Mitotic activity usually very low. Morphology - Pseudofollicles or proliferation centers contain small, medium and large cells. - Prolymphocytes are medium-sized with dispersed chromatin and small nucleoli. - Paraimmunoblasts are medium to large cells with round to oval nuclei, dispersed chromatin, central eosinophilic nucleoli and slightly basophilic cytoplasm. Small Lymphocytic Lymphoma Pseudo-follicle Small Lymphocytic Lymphoma Prolymphocyte Paraimmunoblast Immunophenotype Express weak or dim surface IgM or IgM and IgD, CD5, CD19, CD20 (weak), CD22 (weak), CD79a, CD23, CD43, CD11c (weak). CD10-, cyclin D1-. FMC7 and CD79b negative or weak. Immunophenotype Cases with unmutated Ig variable region genes are reported to be CD38+ and ZAP70+. Immunophenotype Cytoplasmic Ig is detectable in about 5% of the cases. CD5 and CD23 are useful in distinguishing from MCL. Rarely CLL is CD23-. Rarely MCL is CD23+. Perform Cyclin D1 in CD5+/CD23- cases. Some cases with typical CLL morphology may have a different profile (CD5- or CD23-, FMC7+ or CD11c+, or strong sIg, or CD79b+). Genetics Antigen receptor genes: Ig heavy and light chain genes are rearranged. Suggestion of 2 distinct types of SLL defined by the mutational status of the IgVH genes: 40-50% show no somatic mutations of their variable region genes (naïve cells, unmutated).
    [Show full text]
  • 9.7.16 Duke Public
    Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials Discussion Guide Introduction In the last two decades, advances in cancer research and drug development have transformed the cancer care landscape. Certain cancers that were once rapidly fatal can now be managed more like a chronic disease, and patients can experience many months or even years of remission. However, these advances have also created challenges to the rapid development of new therapies. As patients live longer, cancer trial timelines lengthen, as it can take longer to measure whether a treatment has a meaningful impact on survival. One of the key strategies for addressing this challenge and accelerating patient access to new therapies is the development and validation of surrogate endpoints that can be used to measure potential patient benefit at an earlier stage. For drugs intended to treat hematologic cancers, ‘minimal residual disease’ (MRD) is one candidate surrogate endpoint that could be used to develop evidence of efficacy for regulatory review. Between 2012 and 2014, the US Food and Drug Administration (FDA) convened a series of workshops to address issues in MRD detection and use in four cancers: multiple myeloma (MM), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML).1,2,3,4 Though substantial progress has been made since that time in developing the evidence to support the use of MRD as a diagnostic and clinical tool in each of these cancers, questions remain over how best to move forward in terms of its validation as a surrogate endpoint that can be used to support regulatory review.
    [Show full text]
  • Mature B Cell Neoplasms: Retrospective Analysis
    rev bras hematol hemoter. 2 0 1 6;3 8(2):121–127 Revista Brasileira de Hematologia e Hemoterapia Brazilian Journal of Hematology and Hemotherapy www.rbhh.org Original article Mature B cell neoplasms: retrospective analysis of 93 cases diagnosed between 2011 and 2014 in a University Hospital in southern Brazil Chandra Chiappin Cardoso, Ana Carolina Rabello de Moraes, ∗ Joanita Angela Gonzaga Del Moral, Maria Claudia Santos-Silva Universidade Federal de Santa Catarina (UFSC), Florianópolis, SC, Brazil a r t i c l e i n f o a b s t r a c t Article history: Received 12 November 2015 Background: According to the 2008 World Health Organization classification, mature B-cell Accepted 7 February 2016 neoplasms are a heterogeneous group of diseases that include B-cell lymphomas and plasma Available online 9 March 2016 cell disorders. These neoplasms can have very different clinical behaviors, from highly aggressive to indolent, and therefore require diverse treatment strategies. Keywords: Objective: The aim of this study was to assess the profile of 93 patients diagnosed with mature B-cell neoplasms monitored between 2011 and 2014. Mature B-cell neoplasms Diagnosis Methods: A review of patients’ charts was performed and laboratory results were obtained Prognosis using the online system of the Universidade Federal de Santa Catarina. Treatment response Results: The study included 93 adult patients with mature B-cell neoplasms. The most fre- quent subtypes were multiple myeloma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and Burkitt’s lymphoma. The median age at diagnosis was 58 years with a male-to-female ratio of 1.3:1.
    [Show full text]
  • Multiple Myeloma
    Multiple myeloma What is multiple myeloma? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines www.anticancerfund.org www.esmo.org MULTIPLE MYELOMA: A GUIDE FOR PATIENTS PATIENT INFORMATION BASED ON ESMO CLINICAL PRACTICE GUIDELINES This guide for patients has been prepared by the Anticancer Fund as a service to patients, to help patients and their relatives better understand the nature of multiple myeloma and appreciate the best treatment choices available according to the subtype of disease. We recommend that patients ask their doctors about what tests or types of treatments are needed for their type and stage of disease. The medical information described in this document is based on the clinical practice guidelines of the European Society for Medical Oncology (ESMO) for the management of multiple myeloma. This guide for patients has been produced in collaboration with ESMO and is disseminated with the permission of ESMO. It has been written by a medical doctor and reviewed by two oncologists from ESMO including the leading author of the clinical practice guidelines for professionals. It has also been reviewed by representatives from the European Oncology Nursing Society (EONS) and the patient representative from ESMO’s Patient Advocates Working Group. More information about the Anticancer Fund: www.anticancerfund.org More information about the European Society for Medical Oncology: www.esmo.org For words marked with an asterisk, a definition is provided at the end of the document. Multiple myeloma: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2017.1 Page 1 This document is provided by the Anticancer Fund with the permission of ESMO.
    [Show full text]
  • A Challenging Case of Anaplastic Large‑Cell Lymphoma with Primary Bony Presentation
    Published online: 2019-04-16 Case Report A challenging case of anaplastic large‑cell lymphoma with primary bony presentation ABSTRACT Anaplastic large‑cell lymphoma (ALCL) is a distinct type of T‑cell lymphoma showing varied clinicopathological features. The clinical entities identified are systemic and primary cutaneous types. ALK+ ALCL are more common in childhood with predominant nodal presentation. Extranodal involvement is commonly seen in the skin, bones, soft tissue, lung, liver, etc., Here, we present an intriguing case of ALK+ ALCL in an adult patient primarily presenting as multiple bony lytic lesions. Keywords: Anaplastic large‑cell lymphoma ALK+, bony lytic lesions, extranodal INTRODUCTION showed a neutrophillic leukocytosis. No atypical cells were noted. Anaplastic large‑cell lymphoma (ALCL) is a definite type of T‑cell lymphoma showing varied clinicopathological features. Biochemical investigations were ordered consisting of The various entities identified clinically are systemic and alpha‑fetoprotein, carcinoembryonic antigen, serum primary cutaneous types. ALK+ ALCL are more common in light chains, protein electrophoresis, serum calcium, childhood with predominant nodal presentation. Extranodal Vitamin D, and lactate dehydrogenase (LDH). All the results involvement is commonly seen in the skin, bones, soft tissue, were normal except for Vitamin D and LDH levels which lung, liver, etc., and predominantly present as an advanced were <3 ng/ml (normal 20–32 ng/ml), and LDH was 588 U/L stage disease (III–IV). Patients generally have B‑symptoms, (normal 208–308 U/L). especially high fever. ALK‑negative ALCL is a provisional entity in the WHO 2008 classification.[1] The presence of ALK‑NPM Positron emission tomography‑computed tomography mutation heralds a good prognosis, hence subclassifying (PET‑CT) performed showed multifocal expansile lesion them into ALK+/− is important.
    [Show full text]
  • Multiple Myeloma: High Incidence of Chromosomal Aneuploidy As Detected by Interphase Fluorescence /// Situ Hybridization
    [CANCER RESEARCH 55, 3854-3859, September 1, 1995] Multiple Myeloma: High Incidence of Chromosomal Aneuploidy as Detected by Interphase Fluorescence /// Situ Hybridization Johannes Drach,1 Judith Schuster, Hadwiga Nowotny, Jutta Angerler, Friederike Rosenthal, Michael Fiegl, Christian Rothermundt, Andrea Gsur, Ulrich Jäger,Renate Heinz, Klaus Lechner, Heinz Ludwig, and Heinz Huber First Department of Internal Medicine, Division of Clinical Oncology [J. D., J. A., F. R., M. F., C. R.. A. G., H. H.I and Division of Hematology and Hemosiesiolog\ [U. J., K. L.\, University of Vienna, Währinger Cartel 18-20, A-1090 Vienna: Ludwig Bollynann-lnstitule far Leukemia Research and Hematology. Hanusch Hospital ¡H.N.. R. H.¡. Vienna; and First Department of Internili Medicine with Oncolog\. Wilhelminenspital. Vienna [J. S., H. L], Austria ABSTRACT because previous cytogenetic studies suggested preferential involve ment of these chromosomes in karyotypic abnormalities in MM Because metaphase cytogenetic studies in multiple myeloma (MM) are (1-14). In cases with successful karyotyping, we compared FISH hampered by a low proliferative activity of myeloma cells in vitro,inter- results with those obtained by conventional cytogenetics. We also phase cytogenetics by means of fluorescence in situ hybridization (FISH) should improve the detection of chromosomal abnormalities in MM. We investigated whether there was any correlation between specific therefore investigated chromosomal aneuploidy in 36 patients with MM chromosomal aberrations and clinical parameters. using interphase FISH and a-satellite DNA probes for chromosomes 1, 3, 7, 8, 11, 12, 16, 17, 18, and X. By FISH, myeloma cells from 32 patients MATERIALS AND METHODS (88.9%) were aneuploid for at least one of the chromosomes examined.
    [Show full text]